Literature DB >> 8646042

Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age.

A H Briggs1, M J Sculpher, R P Logan, J Aldous, M E Ramsay, J H Baron.   

Abstract

OBJECTIVE: To assess the cost effectiveness of screening for and eradicating Helicobacter pylori in patients under 45 years of age presenting with dyspepsia.
DESIGN: A decision analytic model composed of a decision tree to represent the epidemiology of dyspepsia and a Markov process to model the outcomes of treatment. PATIENTS: Patients under the age of 45 years presenting to their general practitioner with (peptic type) dyspepsia.
INTERVENTIONS: Conventional empirical treatment with healing and maintenance doses of cimetidine v eradication treatment solely in patients with confirmed peptic ulcer; and conventional empirical treatment for all dyspeptic patients compared with the use of a serology test to identify patients with H pylori, who then receive endoscopy to investigate the presence of peptic ulcer disease and, when disease is found, are given eradication treatment with a breath test to confirm successful eradication. MAIN OUTCOME MEASURES: Expected cumulative costs over a period of 10 years. The proportion of time patients spend without a recurrent ulcer.
RESULTS: After receiving eradication treatment, patients with confirmed ulcer spend an average of 99% of their time free from recurrent ulcer disease compared with 95% after treatment with cimetidine. Eradication treatment costs less than that with cimetidine. When the initial cost of identifying appropriate patients to receive eradication treatment is added to the analysis, however, these cost savings take almost eight years to accrue.
CONCLUSIONS: Enthusiasm for introducing testing for and eradication of H pylori for dyspeptic patients in general practice should be tempered by an awareness that cost savings may take many years to realise.

Entities:  

Mesh:

Year:  1996        PMID: 8646042      PMCID: PMC2350996          DOI: 10.1136/bmj.312.7042.1321

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  15 in total

Review 1.  Practical pharmacology and cost-effective management of peptic ulcer disease.

Authors:  K D Katz; D Hollander
Journal:  Am J Surg       Date:  1992-03       Impact factor: 2.565

2.  Cost-effectiveness of cimetidine maintenance therapy in chronic gastric and duodenal ulcer.

Authors:  B Pym; J Sandstad; P Seville; K Byth; W R Middleton; N J Talley; D W Piper
Journal:  Gastroenterology       Date:  1990-07       Impact factor: 22.682

3.  Salivary antibodies to Helicobacter pylori: screening dyspeptic patients before endoscopy.

Authors:  P Patel; M A Mendall; S Khulusi; N Molineaux; J Levy; J D Maxwell; T C Northfield
Journal:  Lancet       Date:  1994-08-20       Impact factor: 79.321

4.  Refractory duodenal ulcer.

Authors:  K D Bardhan
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

5.  Longitudinal study of influence of Helicobacter pylori on current risk of duodenal ulcer relapse. The Hvidovre Ulcer Project Group.

Authors:  M R Clausen; M B Franzmann; C Holst; T I Sørensen; P Christoffersen; P Matzen; E Krag
Journal:  Scand J Gastroenterol       Date:  1992-05       Impact factor: 2.423

6.  Guidelines on appropriate indications for upper gastrointestinal endoscopy. Working Party of the Joint Committee of the Royal College of Physicians of London, Royal College of Surgeons of England, Royal College of Anaesthetists, Association of Surgeons, the British Society of Gastroenterology, and the Thoracic Society of Great Britain.

Authors:  A T Axon; G D Bell; R H Jones; M A Quine; R F McCloy
Journal:  BMJ       Date:  1995-04-01

7.  Endoscopic findings in patients with ulcer-like dyspepsia.

Authors:  M Edenholm; R Gustavsson; O Jansson; H Lingfors; O Nilsson; T Söderlind; L Titusson; A Thulin
Journal:  Scand J Gastroenterol Suppl       Date:  1985

8.  Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection.

Authors:  J Labenz; G Börsch
Journal:  Am J Gastroenterol       Date:  1994-10       Impact factor: 10.864

9.  Evaluation of dyspepsia and functional gastrointestinal disorders: a cost-benefit analysis of different approaches.

Authors:  A Sonnenberg; W F Townsend; A D Müller
Journal:  Eur J Gastroenterol Hepatol       Date:  1995-07       Impact factor: 2.566

Review 10.  Review article: treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence.

Authors:  G N Tytgat
Journal:  Aliment Pharmacol Ther       Date:  1994-08       Impact factor: 8.171

View more
  30 in total

Review 1.  Randomised controlled trials in primary care: case study.

Authors:  S Wilson; B C Delaney; A Roalfe; L Roberts; V Redman; A M Wearn; F D Hobbs
Journal:  BMJ       Date:  2000-07-01

Review 2.  Selecting a decision model for economic evaluation: a case study and review.

Authors:  J Karnon; J Brown
Journal:  Health Care Manag Sci       Date:  1998-10

Review 3.  An introduction to Markov modelling for economic evaluation.

Authors:  A Briggs; M Sculpher
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

Review 4.  Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.

Authors: 
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

5.  Management of dyspeptic patients by general practitioners and specialists.

Authors:  V Stanghellini; C Tosetti; G Barbara; B Salvioli; R De Giorgio; R Corinaldesi
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

6.  Do economic evaluations of targeted therapy provide support for decision makers?

Authors:  Ilia L Ferrusi; Natasha B Leighl; Nathalie A Kulin; Deborah A Marshall
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

7.  Management of young dyspeptic patients in the community.

Authors:  T C Tham
Journal:  Postgrad Med J       Date:  1997-11       Impact factor: 2.401

8.  Pragmatic eradication of H. pylori.

Authors:  A B Hawthorne; K Hawthorne
Journal:  Br J Gen Pract       Date:  1997-10       Impact factor: 5.386

9.  Cost effectiveness of screening for and eradication of Helicobacter pylori in young patients with dyspepsia. Studies'assumptions are removed from clinical practice.

Authors:  I Trimble; C Derrett
Journal:  BMJ       Date:  1996-09-07

10.  Cost effectiveness of screening for and eradication of Helicobacter pylori in young patients with dyspepsia. Costs will probably vary according to local data.

Authors:  S Pugh
Journal:  BMJ       Date:  1996-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.